World / Health & Beauty
No quick fix for diabetes risk
14.03.2010 18:03
bbc.co.uk
Exercise and diet are key to prevent diabetes in high-risk people, say researchers who found two drug treatments offer no benefit.
World
Health & Beauty
NIH studying progesterone to treat traumatic brain injuries
14.03.2010 14:16
usatoday.com
A small study, now being expanded, shows promise for the female hormone best known for playing a key role in maintaining pregnancy.
USA
Health & Beauty
Heart health: Doctors devise less invasive valve surgery
14.03.2010 14:16
usatoday.com
A new study shows that leaky heart valves can be fixed without major surgery by guiding a clip into place from an incision in ...
USA
Health & Beauty
Your Health: Vulnerability to ankle sprains varies with age
14.03.2010 14:16
usatoday.com
Men under 30, women over 30 most fef at risk
USA
Health & Beauty
Tricor doesn't lower diabetics' heart risk in large study
14.03.2010 14:16
usatoday.com
The drugmaker argues that the patients used in the study did not qualify for treatment with fenofibrate and therefore did not ...
USA
Health & Beauty
Allergy sufferers journey into the season of symptoms
14.03.2010 14:16
usatoday.com
Seasonal allergies won't kill you, but they sure can knock you down. USA TODAY sorts through the latest allergy research.
USA
Health & Beauty
No heart benefit seen with fibrates in diabetics
14.03.2010 06:00
reuters.com
ATLANTA (Reuters) - Adding a triglyceride lowering drug to cholesterol fighting statins provided no additional protection from heart attack, stroke and death from heart disease in patients with Type 2 diabetes, according to data from a large study.
World
Health & Beauty
Siemens Wireless Digital Radiography Boosts Patient Capacity
14.03.2010 04:14
medicalnewstoday.com
Portsmouth Hospitals NHS Trust has installed a total of ten Ysio wi-D™ Digital Radiography (DR) systems from Siemens Healthcare. Queen Alexandra Hospital will support in and outpatient, adult, paediatric and emergency imaging needs with eight DR systems...
World
Radiology
Two Phase 3 Trials Of Sunitinib With Commonly Used Chemotherapies In Advanced Breast Cancer Did Not Meet The Primary Endpoint
14.03.2010 04:12
medicalnewstoday.com
Pfizer Inc. announced today that two Phase 3 studies of Sutent® (sunitinib malate) in advanced breast cancer did not meet their primary endpoints...
World
Cancer
English